ESMO 2020 | EPIC-OPC: testing for only p16 can lead to oropharyngeal cancer misclassification

Miren Taberna, MD, PhD, L’Hospitalet de Llobregat , Barcelona, Spain, discusses the findings of the EPIC-OPC study investigating dual p16 and HPV testing for determining prognosis in oropharyngeal cancer. Prognosis was not the same for patients across the subgroups p16+HPV+, p16+HPV-, p16-HPV+. This indicates that only testing for p16 can lead to misclassification of disease and a wider set of biomarkers should be used. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).